ECRIN’s and the SCTO’s roles as COVID-19 fosters innovation and catalyses cooperation amongst European clinical research actors

Uncoordinated and fragmented research activities were the scientific community’s early reactions to the COVID-19 pandemic, with researchers planning and running many small stand‐alone trials or observational studies of single‐agent uses. In this article, we discuss actions that were taken by the European Clinical Research Infrastructure Network (ECRIN) and its national partner the Swiss Clinical Trial Organisation (SCTO) to address the issue of uncoordinated clinical research.